| scholarly article | Q13442814 |
| P2093 | author name string | C Renner | |
| S Hansen | |||
| C Klein | |||
| T A Holak | |||
| R A Engh | |||
| W Voelter | |||
| R Stoll | |||
| R Schumacher | |||
| B Kaluza | |||
| F Hesse | |||
| P Mühlhahn | |||
| S Palme | |||
| M Kamionka | |||
| A Belling | |||
| T Rehm | |||
| W Zeslawski | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 336-344 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. | |
| P478 | volume | 40 |
| Q41880343 | 1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. |
| Q38603245 | 2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists |
| Q37671257 | A conserved mechanism for binding of p53 DNA-binding domain and anti-apoptotic Bcl-2 family proteins |
| Q39888273 | A function for the RING finger domain in the allosteric control of MDM2 conformation and activity |
| Q34754934 | An antibody-free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST-HDM2 recombinant protein |
| Q42742476 | Apoptosis in health and disease and modulation of apoptosis for therapy: An overview |
| Q36017772 | Apoptosis-based therapies and drug targets |
| Q37026970 | Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2 |
| Q34080613 | Beta-peptides with improved affinity for hDM2 and hDMX. |
| Q39952074 | Biochemical characterisation of TCTP questions its function as a guanine nucleotide exchange factor for Rheb |
| Q52970552 | Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action. |
| Q38769135 | Characterization of the Fluorescence Properties of 4-Dialkylaminochalcones and Investigation of the Cytotoxic Mechanism of Chalcones |
| Q34079481 | Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism |
| Q38895241 | Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors |
| Q38364115 | Computer applications for prediction of protein-protein interactions and rational drug design. |
| Q42371971 | Coumarin-chalcone hybrid instigates DNA damage by minor groove binding and stabilizes p53 through post translational modifications. |
| Q74403380 | Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction |
| Q35010309 | Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells |
| Q64240893 | Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists |
| Q34975832 | Dietary chalcones with chemopreventive and chemotherapeutic potential |
| Q34379259 | Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors |
| Q37701743 | Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. |
| Q37283483 | Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. |
| Q38707609 | Diverse Molecular Targets for Chalcones with Varied Bioactivities |
| Q42055434 | Docking Analysis and Multidimensional Hybrid QSAR Model of 1,4-Benzodiazepine-2,5-Diones as HDM2 Antagonists |
| Q35207883 | Drug discovery in the ubiquitin regulatory pathway |
| Q38191796 | Drugging the p53 pathway: understanding the route to clinical efficacy |
| Q36558129 | Drugs targeting protein-protein interactions |
| Q51560838 | Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer. |
| Q46967017 | Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse |
| Q34368432 | Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. |
| Q92674152 | Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction |
| Q35919802 | Hydrophobic Interactions Are a Key to MDM2 Inhibition by Polyphenols as Revealed by Molecular Dynamics Simulations and MM/PBSA Free Energy Calculations |
| Q51026030 | In vitro folding and characterization of the p53 DNA binding domain. |
| Q35058579 | Inhibiting the p53-MDM2 interaction: an important target for cancer therapy |
| Q36040768 | Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma |
| Q37855826 | Inhibitors of MDM2 and MDMX: a structural perspective. |
| Q36392660 | Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program |
| Q34425447 | Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling |
| Q39989774 | Isoquinolin-1-one inhibitors of the MDM2-p53 interaction |
| Q36294472 | Mdm2 in growth signaling and cancer |
| Q38865504 | Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction. |
| Q39535776 | Molecular Dynamics Investigation on the Inhibition of MDM2-p53 Interaction by Polyphenols |
| Q27021479 | Molecular targeted approaches to cancer therapy and prevention using chalcones |
| Q81042317 | NMR structure of a complex between MDM2 and a small molecule inhibitor |
| Q34351264 | Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. |
| Q57496075 | Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine |
| Q35939102 | Novel activators of the tumour suppressor p53. |
| Q37680961 | Patented inhibitors of p53-Mdm2 interaction (2006 - 2008). |
| Q37689194 | Patented small molecule inhibitors of p53-MDM2 interaction |
| Q37262594 | Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction. |
| Q35559055 | Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases |
| Q36292878 | Promoting apoptosis as a strategy for cancer drug discovery |
| Q34804863 | Prospects for cationic polymers in gene and oligonucleotide therapy against cancer |
| Q37114139 | Protein-protein interactions as targets for small-molecule therapeutics in cancer |
| Q34459889 | Protein-protein interfaces: mimics and inhibitors |
| Q37524156 | Recent advances in validating MDM2 as a cancer target. |
| Q30329984 | Rescuing the function of mutant p53. |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q50072047 | Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists†. |
| Q24306351 | Shugoshin is a Mad1/Cdc20-like interactor of Mad2 |
| Q34328638 | Signaling pathways in apoptosis as potential targets for cancer therapy |
| Q37806669 | Small-Molecule Inhibitors of the p53-MDM2 Interaction |
| Q98894841 | Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives |
| Q29617758 | Small-molecule inhibitors of protein-protein interactions: progressing towards the dream |
| Q24651380 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy |
| Q33193145 | Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions |
| Q28822250 | Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) |
| Q40373998 | Structural details on mdm2-p53 interaction |
| Q47588107 | Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics |
| Q34159322 | Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death |
| Q58751153 | Synthesis, Structure, and in vitro Antitumor Activity of Some Glycoside Derivatives of Ferrocenyl-Chalcones and Ferrocenyl-Pyrazolines |
| Q36723211 | Synthetic non-peptide mimetics of alpha-helices |
| Q35030217 | Targeting MDM2-p53 interaction for cancer therapy: are we there yet? |
| Q35903526 | Targeting the p53-MDM2 interaction to treat cancer |
| Q37489930 | The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment |
| Q51246050 | The Mechanism of p53 Rescue by SUSP4. |
| Q34335012 | The central region of HDM2 provides a second binding site for p53. |
| Q34459318 | The re-emergence of natural products for drug discovery in the genomics era. |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q30380490 | Therapeutic considerations for Mdm2: not just a one trick pony |
| Q40127650 | Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo |
| Q58771668 | Trans-chalcone increases p53 activity via DNAJB1/HSP40 induction and CRM1 inhibition |
| Q44420220 | Transcriptional suppression of the HIV promoter by natural compounds |
| Q27680560 | Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction |
| Q48228108 | Unambiguous Identification of β-Tubulin as the Direct Cellular Target Responsible for the Cytotoxicity of Chalcone by Photoaffinity Labeling |
| Q35141470 | Utilizing NMR to study the structure of growth-inhibitory proteins |
| Q36163707 | p53: twenty five years understanding the mechanism of genome protection |
Search more.